ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
More than 20 drug companies have joined to launch the AMR Action Fund, a partnership that aims to bring 2–4 new antibiotics to patients by 2030. The companies say they have so far raised nearly $1 billion to support research into combating antimicrobial resistance (AMR). Although some 700,000 people die every year due to AMR, many companies have exited antibiotic R&D, and others have declared bankruptcy, because it’s difficult to make money selling a product that must be used sparingly.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X